118 related articles for article (PubMed ID: 12625812)
41. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
[TBL] [Abstract][Full Text] [Related]
42. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
43. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
44. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
Eivindson M; Grønbaek H; Skogstrand K; Thorsen P; Frystyk J; Flyvbjerg A; Dahlerup JF
Scand J Gastroenterol; 2007 Apr; 42(4):464-70. PubMed ID: 17454856
[TBL] [Abstract][Full Text] [Related]
45. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
46. Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies.
Katz LH; Kopylov U; Fudim E; Yavzori M; Picard O; Ungar B; Eliakim R; Ben-Horin S; Chowers Y
Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):491-8. PubMed ID: 24613656
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment.
Zeissig S; Bojarski C; Buergel N; Mankertz J; Zeitz M; Fromm M; Schulzke JD
Gut; 2004 Sep; 53(9):1295-302. PubMed ID: 15306588
[TBL] [Abstract][Full Text] [Related]
48. Infliximab therapy for pediatric Crohn's disease.
Veres G; Baldassano RN; Mamula P
Expert Opin Biol Ther; 2007 Dec; 7(12):1869-80. PubMed ID: 18034652
[TBL] [Abstract][Full Text] [Related]
49. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
50. [Remicade (infliximab) in the treatment of Crohn disease].
Brazier F; Delcenserie R; Dupas JL
Presse Med; 2000 Sep; 29(16):1463-4. PubMed ID: 11039091
[No Abstract] [Full Text] [Related]
51. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
52. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab.
Ogawa K; Matsumoto T; Esaki M; Torisu T; Iida M
J Crohns Colitis; 2012 Jun; 6(5):529-35. PubMed ID: 22398057
[TBL] [Abstract][Full Text] [Related]
53. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
54. Infliximab.
Valle E; Gross M; Bickston SJ
Expert Opin Pharmacother; 2001 Jun; 2(6):1015-25. PubMed ID: 11585004
[TBL] [Abstract][Full Text] [Related]
55. Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease.
Di Sabatino A; Biancheri P; Piconese S; Rosado MM; Ardizzone S; Rovedatti L; Ubezio C; Massari A; Sampietro GM; Foschi D; Porro GB; Colombo MP; Carsetti R; MacDonald TT; Corazza GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1891-7. PubMed ID: 20848485
[TBL] [Abstract][Full Text] [Related]
56. Increased levels of NF-kappaB inhibitors (IkappaBalpha and IkappaBgamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatment.
Guidi L; Costanzo M; Ciarniello M; De Vitis I; Pioli C; Gatta L; Pace L; Tricerri A; Bartoloni C; Coppola L; Balistreri P; Doria G; Fedeli G; Gasbarrini GB
Int J Immunopathol Pharmacol; 2005; 18(1):155-64. PubMed ID: 15698520
[TBL] [Abstract][Full Text] [Related]
57. Contrast-enhanced ultrasonography with SonoVue after infliximab therapy in Crohn's disease.
Guidi L; De Franco A; De Vitis I; Armuzzi A; Semeraro S; Roberto I; Papa A; Bock E; Gasbarrini G; Fedeli G
Eur Rev Med Pharmacol Sci; 2006; 10(1):23-6. PubMed ID: 16494107
[TBL] [Abstract][Full Text] [Related]
58. Anti-TNF alpha: new therapy for Crohn's disease.
Mikula CA
Gastroenterol Nurs; 1999; 22(6):245-8. PubMed ID: 10855120
[TBL] [Abstract][Full Text] [Related]
59. Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report.
Principi M; Di Leo A; Ingrosso M; Pisani A; Marangi S; Amoruso A; Panella C; Francavilla A; Ierardi E
Immunopharmacol Immunotoxicol; 2004 May; 26(2):243-8. PubMed ID: 15209360
[TBL] [Abstract][Full Text] [Related]
60. Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF-alpha antagonist infliximab.
Reumaux D; Bardin N; Colombel JF; Dignat-George F; Duthilleul P; Vermeire S
Inflamm Bowel Dis; 2007 Oct; 13(10):1315-7. PubMed ID: 17476677
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
